Autoantibodies Are Early Diabetes Warning Signs
|
By LabMedica International staff writers Posted on 09 Mar 2015 |
Detection of autoantibodies directed against pancreatic islet cells can be used to predict the likelihood of a child developing type I diabetes.
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Latest Clinical Chem. News
- International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
- Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer
- Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
- Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer
- Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy
- New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
- Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
- New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
- Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
- Machine Learning Model Uses Routine Lab Tests to Support Heart Failure Classification
- NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
- Multiprotein Plasma Panel Identifies Remission in Vasculitis
- Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
- Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
- FDA Clears Roche Blood Test for Alzheimer’s Amyloid Pathology Assessment
- Blood Test Markers Could Help Identify Older Adults at Risk of Disability
Channels
Molecular Diagnostics
view channel
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read more
Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
Many patients with suspected rare genetic conditions remain undiagnosed even after genome or exome sequencing, leaving clinicians with limited evidence to interpret uncertain variants. Variants of uncertain... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
H.U. Group Holdings Inc. (Tokyo, Japan) and its wholly owned subsidiary Fujirebio announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized the Lumipulse G NfL Blood and Lumipulse G... Read more







